Cilengitide Affects Tumor Compartment, Vascularization and Microenvironment in Experimental Bone Metastases As Shown by Longitudinal ¹⁸F-FDG PET and Gene Expression Analysis

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2012 Dec 12

PMID 23229276

Citations 11

Authors

Maren Bretschi

Caixia Cheng

Hendrik Witt

Antonia Dimitrakopoulou-Strauss

Ludwig G Strauss

Wolfhard Semmler

Tobias Bauerle

Affiliations

Soon will be listed here.

Abstract

Purpose: Aim of this study was to investigate the specific treatment effects of inhibiting αvβ3/αvβ5 integrins by cilengitide in an animal model of breast cancer bone metastases using dynamic (18)F-FDG PET and gene expression analysis.

Methods: For this purpose, nude rats bearing bone metastases were treated with cilengitide, a small molecule inhibitor of αvβ3 and αvβ5 integrins, from day 30 to 55 after tumor cell inoculation of MDA-MB-231 breast cancer cells (25 mg/kg, 5 days per week; n = 8 rats) and compared to control rats (n = 8). Dynamic (18)F-FDG PET data were assessed at days 30, 35 and 55 after tumor cell inoculation determining the vascular fraction VB and the metabolic variables k1-k4. At day 55, genome-wide mRNA expression analysis was performed to assess the treatment-specific expression changes from cilengitide-treated and control rats.

Results: In a longitudinal (18)F-FDG PET study, the vascular fraction VB was significantly decreased in bone metastases between days 30/35, 30/55 and 35/55, whereas the kinetic parameters k1 and k4 were significantly decreased between days 30/55 in skeletal lesions of treated animals. Gene expression analysis from bone metastases at day 55 revealed that tumor-produced integrins (αvβ5) as well as factors relevant for angiogenesis (αvβ3, VEGF, PDGF), bone resorption (PTHrP and RANKL), extracellular matrix remodeling (collagen, CD44) and bone marrow microenvironment (CXCR4) were significantly reduced upon therapy with cilengitide.

Conclusions: Here, we provide evidence that cilengitide inhibits pivotal factors of all compartments of bone metastases including tumor cells, vasculature and bone microenvironment in vivo and by whole-genome transcriptome analysis.

Citing Articles

Distinguishing benign from malignant lesions with high [ Ga]Ga-FAPI-04 uptake in oncology patients: Insights from dynamic total-body [ Ga]Ga-FAPI-04 PET/CT.

Chen R, Yang X, Li L, Zhao H, Huang G, Liu J Eur J Nucl Med Mol Imaging. 2024; 52(4):1345-1353.

PMID: 39665998 DOI: 10.1007/s00259-024-07029-6.

A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αß Binder for the Treatment of Multiple Cancer Types.

Lerchen H, Stelte-Ludwig B, Kopitz C, Heroult M, Zubov D, Willuda J Cancers (Basel). 2022; 14(2).

PMID: 35053556 PMC: 8773721. DOI: 10.3390/cancers14020391.

Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth.

Kreps L, Addison C Int J Mol Sci. 2021; 22(6).

PMID: 33805598 PMC: 7998601. DOI: 10.3390/ijms22062911.

EDIL3 promotes epithelial-mesenchymal transition and paclitaxel resistance through its interaction with integrin αβ in cancer cells.

Gasca J, Flores M, Jimenez-Guerrero R, Saez M, Barragan I, Ruiz-Borrego M Cell Death Discov. 2020; 6:86.

PMID: 33014430 PMC: 7494865. DOI: 10.1038/s41420-020-00322-x.

Inhibition of αvβ3 integrin impairs adhesion and uptake of tumor-derived small extracellular vesicles.

Altei W, Pachane B, Dos Santos P, Ribeiro L, Sung B, Weaver A Cell Commun Signal. 2020; 18(1):158.

PMID: 32988382 PMC: 7520983. DOI: 10.1186/s12964-020-00630-w.

References

Brown J, Coleman R . Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol. 2012; 9(2):110-8. DOI: 10.1038/nrclinonc.2011.197. View

Pedersen M, Holm S, Lund E, Hojgaard L, Kristjansen P . Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia. 2001; 3(1):80-7. PMC: 1505028. DOI: 10.1038/sj.neo.7900133. View

Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R . Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 2007; 67(12):5821-30. DOI: 10.1158/0008-5472.CAN-06-4499. View

Strauss L, Koczan D, Klippel S, Pan L, Cheng C, Willis S . Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med. 2008; 49(8):1238-44. DOI: 10.2967/jnumed.108.051599. View

Curtis T, Vincent P, Homan S, Wheatley E, Saba T . Fibronectin attenuates increased endothelial monolayer permeability after RGD peptide, anti-alpha 5 beta 1, or TNF-alpha exposure. Am J Physiol. 1995; 269(2 Pt 1):L248-60. DOI: 10.1152/ajplung.1995.269.2.L248. View

Cheng C, Komljenovic D, Pan L, Dimitrakopoulou-Strauss A, Strauss L, Bauerle T . Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG. Hell J Nucl Med. 2011; 14(1):15-20. View

Mas-Moruno C, Rechenmacher F, Kessler H . Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2011; 10(10):753-68. PMC: 3267166. DOI: 10.2174/187152010794728639. View

van der Horst G, van den Hoogen C, Buijs J, Cheung H, Bloys H, Pelger R . Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011; 13(6):516-25. PMC: 3114245. DOI: 10.1593/neo.11122. View

Clezardin P . Integrins in bone metastasis formation and potential therapeutic implications. Curr Cancer Drug Targets. 2009; 9(7):801-6. DOI: 10.2174/156800909789760348. View

10.

De S, Razorenova O, McCabe N, OToole T, Qin J, Byzova T . VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A. 2005; 102(21):7589-94. PMC: 1129024. DOI: 10.1073/pnas.0502935102. View

11.

Nemeth J, Cher M, Zhou Z, Mullins C, Bhagat S, Trikha M . Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis. 2003; 20(5):413-20. DOI: 10.1023/a:1025461507027. View

12.

Bauerle T, Merz M, Komljenovic D, Zwick S, Semmler W . Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res. 2010; 16(12):3215-25. DOI: 10.1158/1078-0432.CCR-09-2932. View

13.

Meyer T, Marshall J, Hart I . Expression of alphav integrins and vitronectin receptor identity in breast cancer cells. Br J Cancer. 1998; 77(4):530-6. PMC: 2149929. DOI: 10.1038/bjc.1998.86. View

14.

Li N, Zhang J, Guo S, Min J, Liu L, Su H . Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer. Mol Biol Rep. 2011; 39(3):3029-35. DOI: 10.1007/s11033-011-1065-y. View

15.

Max R, Gerritsen R, Nooijen P, Goodman S, Sutter A, Keilholz U . Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 1997; 71(3):320-4. DOI: 10.1002/(sici)1097-0215(19970502)71:3<320::aid-ijc2>3.0.co;2-#. View

16.

Bauerle T, Komljenovic D, Merz M, Berger M, Goodman S, Semmler W . Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer. 2010; 128(10):2453-62. DOI: 10.1002/ijc.25563. View

17.

Iorns E, Clarke J, Ward T, Dean S, Lippman M . Simultaneous analysis of tumor and stromal gene expression profiles from xenograft models. Breast Cancer Res Treat. 2011; 131(1):321-4. DOI: 10.1007/s10549-011-1784-8. View

18.

Haberkorn U, Hoffend J, Schmidt K, Altmann A, Bonaterra G, Dimitrakopoulou-Strauss A . Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. Eur J Nucl Med Mol Imaging. 2007; 34(12):2011-23. DOI: 10.1007/s00259-007-0520-4. View

19.

Beekman K, Colevas A, Cooney K, DiPaola R, Dunn R, Gross M . Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer. 2006; 4(4):299-302. DOI: 10.3816/CGC.2006.n.012. View

20.

Brown R, Goodman T, Zasadny K, Greenson J, Wahl R . Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol. 2002; 29(4):443-53. DOI: 10.1016/s0969-8051(02)00288-3. View